Parminder Singh
Expertise in
23
conditions

Dr. Parminder Singh

Cardiology
1331 N 7th St Ste 375, 
Phoenix, AZ 
On Staff At
Accepting New Patients
Offers Telehealth
Expertise in
23
conditions
1331 N 7th St Ste 375, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

To help people achieve health for life.

Dr. Singh is highly rated in 23 conditions, according to our data. His top areas of expertise are Arterial Embolism, Angina, Carotid Artery Disease, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement.

His clinical research consists of co-authoring 59 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Guru Nanak Dev University - India
Residency
Wayne State University School Of Medicine
Specialties
Cardiology
Licenses
Internal Medicine in AZ
Board Certifications
American Board Of Internal Medicine
Fellowships
University of Michigan Medical Center
Hospital Affiliations
Banner Estrella Medical Center
Banner Boswell Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Heart And Vascular Center Of Arizona
1331 N 7th St Ste 375, Phoenix, AZ 85006
Other Locations
Cardiac Cath Lab Of Phoenix
1910 E Thomas Rd Ste 101, Phoenix, AZ 85016

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma
A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Pembrolizumab, Tazemetostat
Study Phase: Phase 1/Phase 2
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drugs: Berzosertib, Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
Phase 1 Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Oraxol (Paclitaxel + HM30181A) in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
Phase 1 Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Oraxol (Paclitaxel + HM30181A) in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug, Biological
Study Phase: Phase 1
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Phase II Study Evaluating Combination Chemotherapy + Radiotherapy (RT) With Avelumab in Muscle Invasive Bladder Cancer
Phase II Study Evaluating Combination Chemotherapy + Radiotherapy (RT) With Avelumab in Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: January 06, 2023
Intervention Type: Other, Radiation, Drug
Study Drugs: Avelumab, Cisplatin, 5-Fluorouracil, Mitomycin C
Study Phase: Phase 2
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
View 10 Less Clinical Trials

55 Total Publications

Circulating Tumor DNA in Urothelial Cancer: Practical Applications in Oncology Clinic.
Circulating Tumor DNA in Urothelial Cancer: Practical Applications in Oncology Clinic.
Journal: JCO oncology practice
Published: December 16, 2025
Similar Doctors
Roderick Tung
Expertise in
20
conditions
Dr. Roderick Tung
Cardiology
Expertise in
20
conditions
Dr. Roderick Tung
Cardiology

Banner - University Medicine Heart Institute

755 East McDowell Road, Floor 4, 
Phoenix, AZ 
 (0.2 miles away)
602-521-3090
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I enjoy exercise, cooking, family, traveling, design, golf, tennis, NBA, learning, and making human connections. Dr. Tung is highly rated in 20 conditions, according to our data. His top areas of expertise are Ventricular Tachycardia, Arrhythmias, Heart Block, Cardiac Ablation, and Pacemaker Implantation.

Wilber Su
Expertise in
10
conditions
Dr. Wilber Su
Cardiology
Expertise in
10
conditions
Dr. Wilber Su
Cardiology

Banner - University Medicine Heart Institute

755 East McDowell Road, Floor 4, 
Phoenix, AZ 
 (0.2 miles away)
602-521-3090
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I enjoy traveling and spending time with my wife and three daughters. I also appreciate the chance to use my engineering background for technology consultations. Dr. Su is highly rated in 10 conditions, according to our data. His top areas of expertise are Atrial Fibrillation, Arrhythmias, Ventricular Tachycardia, Cardiac Ablation, and Pacemaker Implantation.

Expertise in
33
conditions
Dr. Reza Arsanjani
Cardiology
Expertise in
33
conditions
Dr. Reza Arsanjani
Cardiology

AZ - Heart Valve

13400 E Shea Blvd, 
Scottsdale, AZ 
 (17.6 miles away)
480-604-2146
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Reza Arsanjani is a Cardiologist in Scottsdale, Arizona. Dr. Arsanjani is highly rated in 33 conditions, according to our data. His top areas of expertise are Mitral Valve Regurgitation, Coronary Heart Disease, Atrial Fibrillation, Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Singh's expertise for a condition
ConditionClose
      View All 23 Advanced Conditions
      View All 62 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile